Literature DB >> 15016850

The last C-terminal residue of VP3, glutamic acid 257, controls capsid assembly of infectious bursal disease virus.

Christophe Chevalier1, Jean Lepault, Bruno Da Costa, Bernard Delmas.   

Abstract

Infectious bursal disease virus (IBDV) is a nonenveloped virus with an icosahedral capsid composed of two proteins, VP2 and VP3, that derive from the processing of the polyprotein NH(2)-pVP2-VP4-VP3-COOH. The virion contains VP1, the viral polymerase, which is both free and covalently linked to the two double-stranded RNA (dsRNA) genomic segments. In this study, the virus assembly process was studied further with the baculovirus expression system. While expression of the wild-type polyprotein was not found to be self-sufficient to give rise to virus-like particles (VLPs), deletion or replacement of the five C-terminal residues of VP3 was observed to promote capsid assembly. Indeed, the single deletion of the C-terminal glutamic acid was sufficient to induce VLP formation. Moreover, fusion of various peptides or small proteins (a green fluorescent protein or a truncated form of ovalbumin) at the C terminus of VP3 also promoted capsid assembly, suggesting that assembly required screening of the negative charges at the C terminus of VP3. The fused polypeptides mimicked the effect of VP1, which interacts with VP3 to promote VLP assembly. The C-terminal segment of VP3 was found to contain two functional domains. While the very last five residues of VP3 mainly controlled both assembly and capsid architecture, the five preceding residues constituted the VP1 (and possibly the pVP2/VP2) binding domain. Finally, we showed that capsid formation is associated with VP2 maturation, demonstrating that the protease VP4 is involved in the virus assembly process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016850      PMCID: PMC371077          DOI: 10.1128/jvi.78.7.3296-3303.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  A second form of infectious bursal disease virus-associated tubule contains VP4.

Authors:  H Granzow; C Birghan; T C Mettenleiter; J Beyer; B Köllner; E Mundt
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization.

Authors:  J S Boyle; C Koniaras; A M Lew
Journal:  Int Immunol       Date:  1997-12       Impact factor: 4.823

3.  Interactions in vivo between the proteins of infectious bursal disease virus: capsid protein VP3 interacts with the RNA-dependent RNA polymerase, VP1.

Authors:  M G Tacken; P J Rottier; A L Gielkens; B P Peeters
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

4.  A non-canonical lon proteinase lacking the ATPase domain employs the ser-Lys catalytic dyad to exercise broad control over the life cycle of a double-stranded RNA virus.

Authors:  C Birghan; E Mundt; A E Gorbalenya
Journal:  EMBO J       Date:  2000-01-04       Impact factor: 11.598

5.  Infectious bursal disease agent: morphology by negative stain electron microscopy.

Authors:  J W Harkness; D J Alexander; M Pattison; A C Scott
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

6.  VP1, the putative RNA-dependent RNA polymerase of infectious bursal disease virus, forms complexes with the capsid protein VP3, leading to efficient encapsidation into virus-like particles.

Authors:  E Lombardo; A Maraver; J R Castón; J Rivera; A Fernández-Arias; A Serrano; J L Carrascosa; J F Rodriguez
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Three-dimensional structure of infectious bursal disease virus determined by electron cryomicroscopy.

Authors:  B Böttcher; N A Kiselev; V Y Stel'Mashchuk; N A Perevozchikova; A V Borisov; R A Crowther
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Role of Ser-652 and Lys-692 in the protease activity of infectious bursal disease virus VP4 and identification of its substrate cleavage sites.

Authors:  N Lejal; B Da Costa; J C Huet; B Delmas
Journal:  J Gen Virol       Date:  2000-04       Impact factor: 3.891

9.  Proteolytic processing in infectious bursal disease virus: identification of the polyprotein cleavage sites by site-directed mutagenesis.

Authors:  A B Sánchez; J F Rodriguez
Journal:  Virology       Date:  1999-09-15       Impact factor: 3.616

10.  The oligomerization domain of VP3, the scaffolding protein of infectious bursal disease virus, plays a critical role in capsid assembly.

Authors:  Antonio Maraver; Ana Oña; Fernando Abaitua; Dolores González; Roberto Clemente; Jose A Ruiz-Díaz; Jose R Castón; Florencio Pazos; Jose F Rodriguez
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more
  14 in total

1.  VP3, a structural protein of infectious pancreatic necrosis virus, interacts with RNA-dependent RNA polymerase VP1 and with double-stranded RNA.

Authors:  Torunn Pedersen; Astrid Skjesol; Jorunn B Jørgensen
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

2.  Electrostatic interactions between capsid and scaffolding proteins mediate the structural polymorphism of a double-stranded RNA virus.

Authors:  Irene Saugar; Nerea Irigoyen; Daniel Luque; José L Carrascosa; José F Rodríguez; José R Castón
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

3.  Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.

Authors:  Elena Pascual; Carlos P Mata; Josué Gómez-Blanco; Noelia Moreno; Juan Bárcena; Esther Blanco; Ariel Rodríguez-Frandsen; Amelia Nieto; José L Carrascosa; José R Castón
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

4.  The endosomal pathway and the Golgi complex are involved in the infectious bursal disease virus life cycle.

Authors:  Laura R Delgui; José F Rodríguez; María I Colombo
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

5.  Structural peptides of a nonenveloped virus are involved in assembly and membrane translocation.

Authors:  Christophe Chevalier; Marie Galloux; Joan Pous; Céline Henry; Jérôme Denis; Bruno Da Costa; Jorge Navaza; Jean Lepault; Bernard Delmas
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Autoproteolytic activity derived from the infectious bursal disease virus capsid protein.

Authors:  Nerea Irigoyen; Damià Garriga; Aitor Navarro; Nuria Verdaguer; José F Rodríguez; José R Castón
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

7.  Both genome segments contribute to the pathogenicity of very virulent infectious bursal disease virus.

Authors:  Olivier Escaffre; Cyril Le Nouën; Michel Amelot; Xavier Ambroggio; Kristen M Ogden; Olivier Guionie; Didier Toquin; Hermann Müller; Mohammed R Islam; Nicolas Eterradossi
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

8.  Structure of a VP1-VP3 complex suggests how birnaviruses package the VP1 polymerase.

Authors:  Mohammad W Bahar; L Peter Sarin; Stephen C Graham; Jances Pang; Dennis H Bamford; David I Stuart; Jonathan M Grimes
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

9.  Different domains of the RNA polymerase of infectious bursal disease virus contribute to virulence.

Authors:  Cyril Le Nouën; Didier Toquin; Hermann Müller; Rüdiger Raue; Katherine M Kean; Patrick Langlois; Martine Cherbonnel; Nicolas Eterradossi
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

10.  Evaluation of a Phylogenetic Marker Based on Genomic Segment B of Infectious Bursal Disease Virus: Facilitating a Feasible Incorporation of this Segment to the Molecular Epidemiology Studies for this Viral Agent.

Authors:  Abdulahi Alfonso-Morales; Liliam Rios; Orlando Martínez-Pérez; Roser Dolz; Rosa Valle; Carmen L Perera; Kateri Bertran; Maria T Frías; Llilianne Ganges; Heidy Díaz de Arce; Natàlia Majó; José I Núñez; Lester J Pérez
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.